Comment
Author: Admin | 2025-04-28
A hard-nosed inhibitor of CYP3A4/5 and P-gp, increased the Cfor saxagliptin through 62% and the AUC close 2. This was associated with a corresponding lessen in the Cand AUC of the dynamic metabolite next to 95% and 91%, severally. In another study, coadministration of a separate dose of saxagliptin (20 mg) and ketoconazole (200 mg every 12 hours at relentless structure), increased the Cand AUC of saxagliptin on 2. This was associated with a corresponding falling off in the Cand AUC of the agile metabolite by 96% and 90%, respectively. Rifampin: Coadministration of a single quantity of saxagliptin (5 mg) and rifampin (600 mg QD at continuous dignified) decreased the Cand AUC of saxagliptin near 53% and 76%, mutatis mutandis, with a corresponding better in C(39%) but no historic convert in the plasma AUC of the full metabolite. Omeprazole: Coadministration of multiple once-daily doses of saxagliptin (10 mg) and omeprazole (40 mg), a CYP2C19 (major) and CYP3A4 substrate, an inhibitor of CYP2C19, and an inducer of MRP-3, did not change the pharmacokinetics of saxagliptin. Aluminum hydroxide + magnesium hydroxide + simethicone: Coadministration of a unique portion of saxagliptin (10 mg) and a fluent containing aluminum hydroxide (2400 mg), magnesium hydroxide (2400 mg), and simethicone (240 mg) decreased the Cof saxagliptin on 26%; in spite of that, the AUC of saxagliptin was unchanged. Famotidine: Dispensation of a choose dosage of saxagliptin (10 mg) 3 hours after a solitary dose of famotidine (40 mg), an inhibitor of hOCT-1, hOCT-2, and hOCT-3, increased
Add Comment